NPM1 and epidermolysis bullosa: In more details, NPM1 mutations have collectively been reported by molecular analyses in nearly 2% of patients diagnosed with MDS, mainly belonging to high-risk cases, categorized as MDS with excess of blasts (MDS-EB), and in around 3% of MDS/MPN cases, mainly classified as chronic myelomonocytic leukemia (CMML), as summarized in Table 1 and Table 2 [37,40,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86].